<DOC>
	<DOCNO>NCT00241345</DOCNO>
	<brief_summary>The purpose trial determine preemptive therapy oral valganciclovir effective intravenous ganciclovir clear cytomegalovirus ( CMV ) viremia determine quantitative CMV polymerase chain reaction ( PCR ) assay patient undergone bone marrow peripheral blood stem cell transplant .</brief_summary>
	<brief_title>Trial Preemptive Treatment With Oral Valganciclovir Compared With Intravenous ( IV ) Ganciclovir Cytomegalovirus Infection After Bone Marrow Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>- To study effect preemptive therapy IV ganciclovir PO valganciclovir determine quantitative CMV PCR . - To determine incidence CMV disease CMV related mortality follow preemptive treatment oral valganciclovir IV ganciclovir . - To compare incidence recurrent CMV viremia treatment PO valganciclovir see treatment IV ganciclovir . - To determine toxicity profile valganciclovir . - To screen mutation UL97 gene patient increase CMV viral load 14 day treatment . - To determine patient treated PO valganciclovir ganciclovir drug level equivalent see historical control subject treat PO valganciclovir .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Patients receive allogeneic peripheral blood stem cell transplant either related unrelated donor Washington University Medical Center . An initial episode CMV viremia . At time randomization : ANC great equal 1000 Age great equal 18 Adequate renal function creatinine clearance great 10 ml/min Total bilirubin less equal 3.0 Current GI graft versus host disease grade IIIIV Development CMV disease prior time first detection CMV viremia PCR Uncontrolled emesis diarrhea ( great equal 4 episode per day ) 2 consecutive day Pregnant nurse female patient Known hypersensitivity ganciclovir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>post transplant</keyword>
	<keyword>Any patient receiving allogeneic bone marrow peripheral blood stem cell transplant Washington University Medical Center</keyword>
</DOC>